Akebia Therapeutics (AKBA) Operating Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Operating Expenses data on file, last reported at $45.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $45.9 million, up 26.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.0 million (up 23.86% YoY), and the FY2025 annual result was $173.2 million, up 17.47% from the prior year.
• Operating Expenses slipped to $45.9 million in Q1 2026 per AKBA's latest filing, from $53.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $88.8 million in Q1 2022 and troughed at $35.3 million in Q2 2024.
• A 5-year average of $48.3 million and a median of $44.9 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses plunged 48.89% in 2023, then jumped 32.64% in 2025.
• A 5-year view of Operating Expenses shows it stood at $64.1 million in 2022, then sank by 43.58% to $36.2 million in 2023, then gained by 11.84% to $40.4 million in 2024, then jumped by 32.64% to $53.6 million in 2025, then decreased by 14.34% to $45.9 million in 2026.
• Business Quant data shows AKBA's Operating Expenses at $45.9 million in Q1 2026, $53.6 million in Q4 2025, and $44.9 million in Q3 2025.